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CONCLUSION: Selection of appropriate second-line
therapy should be based on coverage and local cross-
resistance patterns.
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OBJECTIVES: To compare patient treatment according
to practice guidelines and the Joint Commission on the
Accreditation of Healthcare Organizations (JCAHO)
outcome measures by hospital type. To investigate
various factors associated with patient treatment accord-
ing to guidelines.
METHODS: Data from 2,238 patients with CAP were
collected from 61 hospitals during a 3-month period.
Patient data included demographic, antimicrobial selec-
tion, and outcome data. Univariate/multivariate statisti-
cal analyses were conducted.
RESULTS: Compared to teaching hospitals, a signiﬁ-
cantly higher percentage of patients admitted to commu-
nity hospitals received treatment in accordance with
treatment guidelines (84% versus 78%). Patients admit-
ted to community hospitals received treatment according
to the 1993 American Thoracic Society (ATS) guidelines
(53% versus 46%), whereas patients admitted to teach-
ing hospitals received treatment according to the Centers
for Disease Control and Prevention guidelines (CDC)
(27% versus 21%). A patient level logistic regression
analyses showed that admission to community hospitals
(odds ratio; OR = 1.9, p < 0.001), hospitals with a CAP
care plan (OR = 1.5, p < 0.01), and higher severity of
illness score (OR = 1.1, p < 0.002) were signiﬁcantly asso-
ciated with receiving care according to practice guide-
lines. However, patients admitted to the ICU (OR = 0.04,
p < 0.001) and having a neoplastic disease comorbidity
(OR = 0.45, p < 0.0002) or congestive heart failure (OR
= 0.68, p < 0.021) were signiﬁcantly less likely to receive
treatment according to guidelines. Admission to a small,
medium or large hospital had no signiﬁcant effect on
receiving treatment according to guidelines. Finally, there
was no signiﬁcant difference between hospitals in terms
of data collection for JCAHO Core Performance 
Measures.
CONCLUSIONS: Most patients with CAP are prescribed
antimicrobial drug therapy concomitant with the guide-
lines and hospitals are variably collecting data that will
help achieve the JCAHO core performance measures.
Patients admitted to community hospitals receive treat-
ment in accordance with CAP guidelines more often than
patients admitted to teaching hospitals, controlling for
other factors that impact patient treatment choice.
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OBJECTIVES: To identify the relationship of physician
reported risk factors to the incidence of hospitalizations
after the initiation of Palivizumab (Synagis TM) therapy
for ﬁrst season prophylaxis to respiratory syncytial virus
(RSV).
METHODS: Participants from Caremark’s specialty
pharmacy database who initiated Palivizumab therapy for
the 2001–02 season were analyzed on physician reported
risk factors prior to therapy initiation for one large payer.
These risk factors include, respiratory related hospital-
izations, older siblings, multiple births, exposure to
smoke, chronic illness diagnosis, medical treatment,
daycare and unspeciﬁed risk. We assessed the proportion
of risk factors within the population at the initiation of
therapy for ﬁrst season infant exposure. The relationship
between these risk factors and post-therapy initiation 
hospitalization rates will be assessed using multivariate
analysis. The study period was for participants born after
01 April 2001.
RESULTS: 410 participants (age = 156 +/- 63 days) 
who presented prescriptions for Palivizumab through
Caremark’s Specialty Pharmacy for the 2001–2002 RSV
season were analyzed. On average, infants had 1.23 +/-
1.05 risk factors. We identiﬁed 4.15% of the infants had
a reported respiratory hospitalization prior to initiation
of Palivizumab therapy. Other risk factors prior to
therapy initiation were distributed as follows: 33.9%
Older Siblings, 30.24% Multiple Births, 7.07% Exposure
to Smoke, 5.37% Chronic Illness Diagnosis, 22.2%
Medical Treatment, 10.0% Daycare Exposure, and
14.39% Unspeciﬁed Risk. Post therapy initiation hospi-
talization rates for the 2001–2002 RSV season are cur-
rently being collected and results of the multivariate
analysis will be presented.
CONCLUSION: A priori variables to direct and optimize
therapeutic management of at-risk RSV infant popula-
tions are essential. These ﬁndings on hospitalization rates
associated with physician reported risk factors would
support the decision making of both pharmacy and
provider organizations.
PIN24
WHAT IS THE VALUE OF WARD SUPPLY 
DATA FOR MONITORING ANTIBIOTIC 
USE IN HOSPITAL?
Ofori BD1, Davey PG2
1Ninewells Hospital and Medical School, Dundee, UK;
2University of Dundee, Dundee, UK
